VAISHALI PHARMA Latest Share Price (VAISHALI)
TODAY IN ONE LINE
VAISHALI dropped 3.5% on above-average volume (764087.0x avg), lagging Nifty's -1.1% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹97.85 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
VAISHALI PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.27x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 76.7% YoY
- ●Poor Capital ReturnsLow ROE of 5.8%
- ●Promoter SellingPromoter holding decreased by 1.07% QoQ
Latest VAISHALI PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
VAISHALI PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for VAISHALI PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
VAISHALI PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for VAISHALI PHARMA — derived from the latest tape, not yesterday's close.
VAISHALI PHARMA last traded at ₹7.54 with an intraday range of ₹7.5–₹8.25 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹7.54| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 9.53 | +1.99 | +26.35% |
| R3 | 8.78 | +1.24 | +16.40% |
| R2 | 8.51 | +0.97 | +12.91% |
| R1 | 8.03 | +0.49 | +6.45% |
| PIVOT | 7.76 | 0.22 | 2.96% |
| CURRENT | 7.54 | — | — |
| S1 | 7.28 | -0.26 | -3.49% |
| S2 | 7.01 | -0.53 | -6.98% |
| S3 | 6.53 | -1.01 | -13.44% |
| S4 | 5.78 | -1.76 | -23.39% |
VAISHALI is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹7.71–₹8.25
Trading Below opening range, showing Bearishness
VAISHALI PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for VAISHALI PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
VAISHALI PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹97.85 Cr. and reported EPS of ₹0.12.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 109 | 109 ▲ 0.0% |
| Other Income | 4 | 4 ▲ 0.0% |
| Total Income | 113 | 113 ▲ 0.0% |
| 95 | 95 ▲ 0.0% | |
| Gross ProfitDerived | 14 | 14 ▲ 0.0% |
| Gross Margin %Derived | 12.55% | 12.55% |
| 10 | 10 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 4 | 4 ▲ 0.0% |
| OPM %Derived | 3.78% | 3.78% |
| 3 | 3 ▲ 0.0% | |
| Profit Before Tax (PBT) | 5 | 5 ▲ 0.0% |
| 1 | 1 ▲ 0.0% | |
| Effective Tax %Derived | 25.16% | 25.16% |
| Total Profit for Period | 4 | 4 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 4 | 4 ▲ 0.0% |
| Net Profit Margin %Derived | 3.83% | 3.83% |
| Earnings Per Share (EPS ₹) | 0.32 | 0.32 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 13 | 13 ▲ 0.0% |
| Share of Profit from Associates/JVs | 0 | 0 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 107 | 107 ▲ 0.0% |
| Material Cost % of RevenueDerived | — | — |
| Employee Cost % of RevenueDerived | 2.68% | 2.68% |
| Other Cost % of RevenueDerived | 6.09% | 6.09% |
| Interest Coverage (x)Derived | 1.79x | 1.79x |
| Period | Mar 2026 | May 2026 | Trend |
|---|---|---|---|
| Revenue from Operations | 109 | 109 ▲ 0.0% | |
| Other Income | 4 | 4 ▲ 0.0% | |
| Total Income | 113 | 113 ▲ 0.0% | |
95 | 95 ▲ 0.0% | ||
| Gross ProfitDerived | 14 | 14 ▲ 0.0% | |
| Gross Margin %Derived | 12.55% | 12.55% | |
10 | 10 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 4 | 4 ▲ 0.0% | |
| OPM %Derived | 3.78% | 3.78% | |
3 | 3 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 5 | 5 ▲ 0.0% | |
1 | 1 ▲ 0.0% | ||
| Effective Tax %Derived | 25.16% | 25.16% | |
| Total Profit for Period | 4 | 4 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 4 | 4 ▲ 0.0% | |
| Net Profit Margin %Derived | 3.83% | 3.83% | |
| Earnings Per Share (EPS ₹) | 0.32 | 0.32 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 13 | 13 ▲ 0.0% | |
| Share of Profit from Associates/JVs | 0 | 0 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 107 | 107 ▲ 0.0% | |
| Material Cost % of RevenueDerived | — | — | |
| Employee Cost % of RevenueDerived | 2.68% | 2.68% | |
| Other Cost % of RevenueDerived | 6.09% | 6.09% | |
| Interest Coverage (x)Derived | 1.79x | 1.79x |
VAISHALI PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at VAISHALI PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
VAISHALI PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for VAISHALI PHARMA.
Our AI distills the core fundamental drivers supporting VAISHALI PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
VAISHALI PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — VAISHALI PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
VAISHALI PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for VAISHALI PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
VAISHALI PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for VAISHALI PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in VAISHALI PHARMA stood at 72.6% of traded volume, against a 20-day average of 66.6%.
VAISHALI PHARMA announcements: results, concalls, ratings, M&A.
Filings VAISHALI PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
VAISHALI PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 58 documents below.
General Updates
Vaishali Pharma Limited has informed the Exchange about General Updates
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Vaishali Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Trading Window
Vaishali Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
Shareholders meeting
Vaishali Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 24, 2026. Further, the…
Shareholders meeting
Vaishali Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 24, 2026
VAISHALI PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue VAISHALI PHARMA has declared, sequenced by announce and record date.
VAISHALI PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About VAISHALI PHARMA: business, sector, key facts.
What VAISHALI PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
VAISHALI PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: VAISHALI.
Vaishali Pharma Limited is an Indian pharmaceutical company with a global reach, primarily involved in the manufacturing and distribution of a wide range of pharmaceutical products. Their business model encompasses both active pharmaceutical ingredients (APIs) and finished formulations, catering to various therapeutic areas.
The company's API portfolio is extensive, covering a broad spectrum of therapeutic classes. This includes antibiotics, anti-ulcer medications, anti-inflammatory drugs, analgesics, antipyretics, anti-malarials, cardiac medications, anti-diabetics, anti-cold and anti-allergic drugs, anti-diarrheal, anti-protozoal and anti-parasitic agents, anti-virals, anti-epileptics, anti-asthmatics, anti-fungals, anti-platelet agents, skeletal muscle relaxants, and anti-helminthics. They also produce a variety of excipients, topical steroids, corticosteroids, and enzymes, crucial components in drug manufacturing.
In addition to APIs, Vaishali Pharma offers a diverse range of finished pharmaceutical formulations. These include antibiotics, anti-platelet agents, laxatives, anti-ulcer medications, anti-asthmatics, anti-malarials, anti-cold and anti-allergic medications, anti-virals, anti-psychotics, cardiac medications, anti-diabetics, anti-inflammatory and analgesic drugs, topical steroids and corticosteroids, anti-fungals, and vitamins. Beyond these core offerings, they also extend their product line to include veterinary products, nutraceuticals, oncology medications, herbal remedies, and surgical products.
Established in 1989 and headquartered in Mumbai, India, Vaishali Pharma Limited has built a substantial presence in the pharmaceutical industry, demonstrating a commitment to providing a comprehensive array of pharmaceutical solutions across various therapeutic categories and market segments. Their integrated approach, encompassing both API and formulation development and manufacturing, allows for greater control over product quality and supply chain efficiency.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about VAISHALI PHARMA (VAISHALI).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of VAISHALI PHARMA (VAISHALI)?
The current share price of VAISHALI PHARMA (VAISHALI) is ₹7.54. Today, the stock has declined by ₹0.27 (3.46%), trading in a range of ₹7.50 to ₹8.25. The stock opened at ₹8.25 with a trading volume of 71,977 shares.
02What is the 52-week high and low price of VAISHALI PHARMA stock?
The 52-week high price of VAISHALI PHARMA (VAISHALI) is ₹11.15, while the 52-week low is ₹4.75. Currently trading at ₹7.54, the stock is 58.74% above its 52-week low and 32.38% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
03What is the dividend yield of VAISHALI PHARMA and when is the next dividend?
VAISHALI PHARMA offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹7.54, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
04How is VAISHALI PHARMA stock performing today in the market?
VAISHALI PHARMA stock opened at ₹8.25 and is currently trading at ₹7.54, showing a decline of ₹0.27 (3.46%). The intraday high is ₹8.25 and low is ₹7.50. The trading volume stands at 71,977 shares, indicating moderate market participation today.
05What is the market capitalization of VAISHALI PHARMA?
VAISHALI PHARMA has a market capitalization of ₹97.85 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹7.54) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
06What is the ROE and ROCE of VAISHALI PHARMA?
VAISHALI PHARMA has a Return on Equity (ROE) of 5.84% and Return on Capital Employed (ROCE) of 6.37%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
07Which sector and industry does VAISHALI PHARMA belong to?
VAISHALI PHARMA operates in the Healthcare sector and belongs to the Pharmaceuticals industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
08What is the debt-to-equity ratio of VAISHALI PHARMA?
VAISHALI PHARMA has a debt-to-equity ratio of 0.27, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
The data, ratios and commentary about VAISHALI PHARMA (VAISHALI) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.